Complete financial analysis of Bayer Aktiengesellschaft (BAY.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bayer Aktiengesellschaft, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Actron Technology Corporation (8255.TWO) Income Statement Analysis – Financial Results
- American Realty Investors, Inc. (ARL) Income Statement Analysis – Financial Results
- Bolivar Mining Corp. (BOLV) Income Statement Analysis – Financial Results
- PT FKS Multi Agro Tbk (FISH.JK) Income Statement Analysis – Financial Results
- Antec Inc. (6276.TWO) Income Statement Analysis – Financial Results
Bayer Aktiengesellschaft (BAY.WA)
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases, as well as collaboration with Bicycle Therapeutics to develop bicyclic peptides. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.64B | 50.74B | 44.08B | 41.40B | 43.55B | 39.59B | 35.02B | 46.77B | 46.32B | 42.24B | 40.16B | 39.76B | 36.53B | 35.09B | 31.17B | 32.92B | 32.39B | 28.96B | 27.36B | 29.74B | 28.52B | 28.98B | 28.99B | 29.56B | 27.32B | 28.06B |
| Cost of Revenue | 19.75B | 19.87B | 16.82B | 19.14B | 17.47B | 17.01B | 11.38B | 20.30B | 21.16B | 20.27B | 19.35B | 19.06B | 17.98B | 17.10B | 15.14B | 16.46B | 16.35B | 15.28B | 15.02B | 17.37B | 16.80B | 17.53B | 16.57B | 15.61B | 13.59B | 12.51B |
| Gross Profit | 27.89B | 30.87B | 27.27B | 22.26B | 26.08B | 22.58B | 23.63B | 26.47B | 25.17B | 21.97B | 20.81B | 20.70B | 18.55B | 17.99B | 16.03B | 16.46B | 16.03B | 13.68B | 12.35B | 12.37B | 11.71B | 11.46B | 12.42B | 13.95B | 13.74B | 15.55B |
| Gross Profit Ratio | 58.54% | 60.84% | 61.85% | 53.77% | 59.89% | 57.03% | 67.49% | 56.61% | 54.33% | 52.02% | 51.82% | 52.06% | 50.79% | 51.26% | 51.44% | 50.01% | 49.51% | 47.25% | 45.12% | 41.59% | 41.07% | 39.54% | 42.83% | 47.20% | 50.27% | 55.42% |
| Research & Development | 5.63B | 6.57B | 5.41B | 7.13B | 5.34B | 5.25B | 4.50B | 4.67B | 4.28B | 3.57B | 3.19B | 3.01B | 2.93B | 3.05B | 2.75B | 2.65B | 2.58B | 2.30B | 1.88B | 2.11B | 2.41B | 2.53B | 2.49B | 2.38B | 2.14B | 1.81B |
| General & Administrative | 2.45B | 2.84B | 2.96B | 2.88B | 3.89B | 2.73B | 2.03B | 2.26B | 2.10B | 1.74B | 1.88B | 1.87B | 1.71B | 1.65B | 1.62B | 1.65B | 1.77B | 8.13B | 7.15B | 7.86B | 8.16B | 8.02B | 9.16B | 7.78B | 773.00M | 760.00M |
| Selling & Marketing | 12.48B | 14.08B | 12.36B | 13.05B | 12.27B | 12.75B | 11.12B | 12.47B | 12.37B | 11.02B | 10.08B | 9.99B | 8.96B | 8.80B | 7.92B | 8.11B | 7.78B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.68B | 5.34B |
| SG&A | 14.94B | 16.92B | 15.33B | 15.93B | 16.16B | 15.48B | 13.14B | 14.73B | 14.47B | 12.76B | 11.96B | 11.85B | 10.67B | 10.45B | 9.55B | 9.75B | 9.55B | 8.13B | 7.15B | 7.86B | 8.16B | 8.02B | 9.16B | 7.78B | 6.45B | 6.10B |
| Other Expenses | 7.32B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00M | 0.00 | 0.00 | 0.00 | 0.00 | -451.00M | 0.00 | 0.00 | -920.00M | -1.25B | -612.12M | -822.51M | 3.19B | -618.48M | -128.13M | -922.06M | 0.00 | -427.00M |
| Operating Expenses | 27.89B | 23.54B | 20.36B | 22.98B | 21.55B | 22.25B | 17.52B | 19.14B | 18.36B | 16.25B | 15.80B | 15.42B | 14.40B | 15.26B | 13.03B | 12.92B | 13.70B | 10.92B | 9.54B | 10.56B | 12.91B | 9.88B | 11.17B | 10.81B | 9.36B | 7.96B |
| Cost & Expenses | 47.64B | 43.41B | 37.17B | 42.11B | 39.01B | 39.26B | 28.91B | 39.44B | 39.52B | 36.51B | 35.14B | 34.48B | 32.38B | 32.36B | 28.16B | 29.37B | 30.05B | 26.19B | 24.55B | 27.93B | 29.72B | 27.41B | 27.74B | 26.42B | 22.95B | 20.47B |
| Interest Income | 436.00M | 379.00M | 346.00M | 202.00M | 294.00M | 321.00M | 272.00M | 137.00M | 297.00M | 283.00M | 257.00M | 317.00M | 371.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.05B | 1.86B | 1.35B | 1.60B | 1.85B | 1.62B | 871.00M | 978.00M | 1.04B | 940.00M | 899.00M | 907.00M | 1.06B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.02B | 6.50B | 3.06B | 13.26B | 5.37B | 6.35B | 2.66B | 3.74B | 3.33B | 2.94B | 2.90B | 2.96B | 2.77B | 3.56B | 2.81B | 2.72B | 2.71B | 1.91B | 1.83B | 2.32B | 4.73B | 3.32B | 2.52B | 2.15B | 1.81B | 1.54B |
| EBITDA | 10.45B | 13.03B | 10.03B | 10.32B | 10.07B | 9.69B | 8.11B | 10.90B | 9.61B | 8.27B | 8.00B | 7.14B | 6.92B | 6.29B | 5.82B | 6.27B | 5.87B | 4.67B | 4.64B | 3.38B | 3.53B | 4.89B | 4.13B | 5.29B | 6.60B | 9.14B |
| EBITDA Ratio | 21.93% | 25.16% | 22.76% | 24.93% | 23.90% | 17.23% | 23.73% | 23.30% | 21.89% | 20.46% | 19.96% | 21.18% | 18.94% | 17.91% | 18.66% | 19.04% | 15.58% | 16.15% | 16.97% | 13.87% | 12.37% | 16.88% | 12.98% | 17.88% | 22.64% | 32.57% |
| Operating Income | 678.00M | 6.26B | 6.98B | -2.94B | 5.04B | 3.91B | 5.90B | 7.04B | 6.25B | 5.51B | 4.93B | 3.96B | 4.15B | 2.73B | 3.01B | 3.54B | 3.15B | 2.76B | 2.81B | 1.81B | -1.20B | 1.58B | 1.24B | 3.14B | 3.36B | 3.16B |
| Operating Income Ratio | 1.42% | 12.35% | 15.82% | -7.10% | 11.58% | 9.89% | 16.86% | 15.06% | 13.49% | 13.04% | 12.29% | 9.96% | 11.36% | 7.78% | 9.64% | 10.77% | 9.74% | 9.54% | 10.27% | 6.08% | -4.21% | 5.43% | 4.29% | 10.63% | 12.29% | 11.24% |
| Total Other Income/Expenses | -2.30B | -1.59B | -4.86B | -16.54B | -2.19B | -1.60B | -1.33B | -1.74B | -1.73B | -1.09B | -916.00M | -784.00M | -786.00M | -1.01B | -1.14B | -1.19B | -920.00M | -781.94M | -601.15M | -632.19M | 3.19B | -618.48M | -123.63M | -101.15M | -521.00M | -427.00M |
| Income Before Tax | -1.62B | 4.67B | 2.05B | -17.25B | 2.88B | 2.32B | 4.58B | 5.89B | 5.25B | 4.53B | 4.21B | 3.25B | 3.36B | 1.72B | 1.87B | 2.36B | 2.23B | 1.98B | 2.20B | 984.07M | 1.99B | 956.78M | 1.12B | 2.82B | 2.84B | 2.73B |
| Income Before Tax Ratio | -3.40% | 9.20% | 4.64% | -41.67% | 6.61% | 5.86% | 13.07% | 12.59% | 11.32% | 10.71% | 10.48% | 8.17% | 9.21% | 4.90% | 6.00% | 7.16% | 6.90% | 6.84% | 8.03% | 3.31% | 6.98% | 3.30% | 3.87% | 9.53% | 10.38% | 9.72% |
| Income Tax Expense | 1.32B | 504.00M | 1.02B | -1.69B | 450.00M | 607.00M | 1.33B | 1.33B | 1.23B | 1.08B | 1.02B | 752.00M | 891.00M | 411.00M | 511.00M | 636.00M | -72.00M | 453.86M | 640.83M | 384.33M | -643.96M | -106.73M | 153.98M | 1.15B | 818.00M | 1.11B |
| Net Income | -2.94B | 4.15B | 1.00B | -10.50B | 4.09B | 1.70B | 7.34B | 4.53B | 4.11B | 3.43B | 3.19B | 2.45B | 2.47B | 1.30B | 1.36B | 1.72B | 4.71B | 1.69B | 1.59B | 602.68M | -1.26B | 1.06B | 966.56M | 1.67B | 2.00B | 1.61B |
| Net Income Ratio | -6.17% | 8.18% | 2.27% | -25.35% | 9.39% | 4.28% | 20.95% | 9.69% | 8.87% | 8.11% | 7.94% | 6.15% | 6.76% | 3.71% | 4.36% | 5.22% | 14.55% | 5.85% | 5.83% | 2.03% | -4.41% | 3.66% | 3.33% | 5.63% | 7.33% | 5.75% |
| EPS | -2.99 | 4.22 | 1.02 | -10.68 | 4.17 | 1.80 | 8.29 | 5.44 | 4.97 | 4.14 | 3.86 | 2.91 | 2.99 | 1.57 | 1.70 | 2.25 | 6.16 | 2.27 | 1.85 | 1.98 | -1.86 | 1.45 | 1.28 | 2.49 | 2.74 | 2.21 |
| EPS Diluted | -2.99 | 4.22 | 1.02 | -10.68 | 4.17 | 1.80 | 8.29 | 5.44 | 4.97 | 4.14 | 3.86 | 2.91 | 2.99 | 1.57 | 1.70 | 2.09 | 5.72 | 2.27 | 1.85 | 1.98 | -1.86 | 1.45 | 1.28 | 2.49 | 2.74 | 2.21 |
| Weighted Avg Shares Out | 982.42M | 982.42M | 982.42M | 982.42M | 981.69M | 940.76M | 885.19M | 832.50M | 826.95M | 826.95M | 826.95M | 826.95M | 826.95M | 826.95M | 826.01M | 764.34M | 764.34M | 746.46M | 730.34M | 730.34M | 675.58M | 731.46M | 730.00M | 731.48M | 730.66M | 730.32M |
| Weighted Avg Shares Out (Dil) | 982.42M | 982.42M | 982.42M | 982.42M | 981.69M | 940.76M | 885.19M | 832.50M | 826.95M | 826.95M | 826.95M | 826.95M | 826.95M | 826.95M | 826.01M | 824.24M | 823.91M | 791.76M | 730.34M | 730.34M | 675.58M | 731.46M | 730.00M | 731.48M | 730.66M | 730.32M |
Source: https://incomestatements.info
Category: Stock Reports